In a phase 3 study, Crovalimab was found to be efficacious and well tolerated in people with paroxys...
Read moreBe the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​
Get in touch